Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
GI Innovation, Inc.
Atavistik Bio, Inc
Mayo Clinic
Alterome Therapeutics, Inc.
Bayer
Neonc Technologies, Inc.
ViroMissile, Inc.
Rutgers, The State University of New Jersey
Arcus Biosciences, Inc.
Bristol-Myers Squibb
Kaiser Permanente
AstraZeneca
Tizona Therapeutics, Inc
Genentech, Inc.
Eli Lilly and Company
Jonsson Comprehensive Cancer Center
University of Colorado, Denver
MacroGenics
Daiichi Sankyo
Eli Lilly and Company
ImmunityBio, Inc.
Ocellaris Pharma, Inc.
Medical College of Wisconsin
Innate Pharma
National Institutes of Health Clinical Center (CC)
OncoNano Medicine, Inc.
City of Hope Medical Center
Mayo Clinic
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Pittsburgh
Tanabe Pharma America, Inc.
HiFiBiO Therapeutics
DualityBio Inc.
University of Pittsburgh
UNC Lineberger Comprehensive Cancer Center
Rondo Therapeutics
Incyte Corporation
Actym Therapeutics, Inc.
University of Arizona
Chongqing Precision Biotech Co., Ltd
Nurix Therapeutics, Inc.
Sahlgrenska University Hospital
National Institutes of Health Clinical Center (CC)
Pfizer
Washington University School of Medicine
Incyte Corporation
Merck Sharp & Dohme LLC
Jonsson Comprehensive Cancer Center
Cancer Research UK